Amgen to acquire Five Prime Therapeutics for gastric cancer candidate bemarituzumab
Amgen acquisition of Five Prime Therapeutics : Amgen has agreed to acquire Five Prime Therapeutics, a clinical-stage biotech company, for about $1.9 billion, to add a phase 3 ready gastric cancer candidate called bemarituzumab. Based in California, Five Prime Therapeutics is engaged in developing immuno-oncology and targeted cancer therapies. Amgen will acquire the biotech company […]